RM PLC (LON:RM) Stock Buy Rating Reiterated at Peel Hunt; The Target Given is GBX 203.00; Shorts at Biocept (BIOC) Lowered By 4.54%

December 7, 2017 - By Winifred Garcia

RM PLC (LON:RM) had its stock rating noted as Buy by analysts at Peel Hunt. Peel Hunt currently has a GBX 203.00 target price per share on the 151.90M GBP market cap company or 9.95% upside potential. This was released in a note on Thursday, 7 December.

Biocept Incorporated (NASDAQ:BIOC) had a decrease of 4.54% in short interest. BIOC’s SI was 2.54M shares in December as released by FINRA. Its down 4.54% from 2.66M shares previously. With 325,500 avg volume, 8 days are for Biocept Incorporated (NASDAQ:BIOC)’s short sellers to cover BIOC’s short positions. The SI to Biocept Incorporated’s float is 13.48%. The stock decreased 33.04% or $0.38 during the last trading session, reaching $0.77. About 6.29 million shares traded or 965.43% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 31.06% since December 7, 2016 and is downtrending. It has underperformed by 47.76% the S&P500.

Among 3 analysts covering Biocept Inc (NASDAQ:BIOC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 4 analyst reports since August 19, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Wednesday, August 19 with “Buy”. Roth Capital initiated the stock with “Buy” rating in Monday, June 6 report.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $27.09 million. The companyÂ’s cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

Analysts await RM Plc (LON:RM) to report earnings on February, 6. They expect $0.62 EPS, up 10.71% or $0.06 from last year’s $0.56 per share. RM’s profit will be $505,147 for 75.18 P/E if the $0.62 EPS becomes a reality. After $0.58 actual EPS reported by RM Plc for the previous quarter, Wall Street now forecasts 6.90% EPS growth.

Among 3 analysts covering RM PLC (LON:RM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RM PLC has GBX 219 highest and GBX 169 lowest target. GBX 203.33’s average target is 9.06% above currents GBX 186.438 stock price. RM PLC had 29 analyst reports since December 16, 2015 according to SRatingsIntel. On Monday, February 1 the stock rating was maintained by Numis Securities with “Buy”. The stock has “Buy” rating by FinnCap on Wednesday, July 5. Peel Hunt maintained the stock with “Buy” rating in Thursday, December 7 report. As per Thursday, January 19, the company rating was maintained by Peel Hunt. FinnCap maintained RM Plc (LON:RM) on Wednesday, May 4 with “Buy” rating. The stock of RM Plc (LON:RM) earned “Buy” rating by FinnCap on Wednesday, February 15. Peel Hunt maintained RM Plc (LON:RM) on Monday, July 4 with “Buy” rating. On Thursday, March 24 the stock rating was maintained by FinnCap with “Buy”. FinnCap maintained RM Plc (LON:RM) on Monday, July 4 with “Buy” rating. The firm earned “Buy” rating on Monday, January 9 by FinnCap.

The stock increased 15.80% or GBX 25.438 during the last trading session, reaching GBX 186.438. About 11,219 shares traded. RM Plc (LON:RM) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com